Datopotamab deruxtecan
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Trop-2 |
| Clinical data | |
| Pronunciation | da" toe poe' tah mab der" ux tee' kan |
| Trade names | Datroway |
| Other names | DS-1062a, Dato-DXd, datopotamab deruxtecan-dlnk |
| AHFS/Drugs.com | Multum Consumer Information |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Antibody-drug conjugate |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6464H10008N1708O2012S44 |
| Molar mass | 145251.75 g·mol−1 |
Datopotamab deruxtecan, sold under the brand name Datroway, is an anti-cancer medication used for the treatment of breast cancer. It is a Trop-2-directed antibody and topoisomerase inhibitor antibody-drug conjugate.
The most common adverse reactions, including laboratory abnormalities, include stomatitis, nausea, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased hemoglobin, constipation, decreased neutrophils, dry eye, vomiting, increased ALT, keratitis, increased AST, and increased alkaline phosphatase.
Datopotamab deruxtecan was approved for medical use in the United States in January 2025, and in the European Union in April 2025.